// Insilico Medicine saw its revenue jump more than six times to $30.1 million in 2022 from the previous year, according to the filing. The company generates revenue from research and development collaborations with pharmaceutical companies and subscription fees for its generative AI platforms.
根據文件顯示，Insilico Medicine在2022年的收入從前一年的水平增長了超過六倍，達到了3010萬美元。該公司的收入來自於與制藥公司的研發合作以及其生成式人工智能平台的訂閱費用。 https://www.forbes.com/sites/zinnialee/2023/06/29/qiming-backed-ai-drug-discovery-startup-insilico-medicine-files-for-hong-kong-ipo/ //